Technical Analysis for NOVN - Novan, Inc.

Grade Last Price % Change Price Change
grade D 1.5 4.90% 0.07
NOVN closed up 4.9 percent on Friday, March 22, 2019, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical NOVN trend table...

Date Alert Name Type % Chg
Mar 22 Pocket Pivot Bullish Swing Setup 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Above Upper BB Strength 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Up 3 Days in a Row Strength 0.00%
Mar 22 Up 4 Days in a Row Strength 0.00%
Mar 21 Pocket Pivot Bullish Swing Setup 4.90%
Mar 21 Stochastic Reached Overbought Strength 4.90%
Mar 21 Upper Bollinger Band Walk Strength 4.90%

Older signals for NOVN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.
Medical Specialties Organ Systems Infectious Diseases Acne Acne Vulgaris Cutaneous Conditions Fungal Infections Inflammatory Skin Diseases Product Candidates Treatment Of Inflammatory Skin Diseases Wart
Is NOVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 19 Will NOVAN INC (NOVN) Report Negative Q4 Earnings? What You Should Know
Mar 19 Novan and Sato Advance Japan Market and Dermatology Partnership
Mar 11 Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
Mar 5 Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
Mar 4 Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
Feb 28 Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Feb 25 Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
Feb 25 Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
Feb 13 Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
Jan 30 Novan sets FDA meeting on SB206 development plan
See more NOVN news...
Indicators
Indicator Value
52 Week High 3.35
52 Week Low 0.65
Average Volume 55,111
200-Day Moving Average 2.1397
50-Day Moving Average 1.2856
20-Day Moving Average 1.2194
10-Day Moving Average 1.263
Average True Range 0.0988
ADX 15.6
+DI 34.6129
-DI 15.6221
Chandelier Exit (Long, 3 ATRs ) 1.2436
Chandelier Exit (Short, 3 ATRs ) 1.3024
Upper Bollinger Band 1.4359
Lower Bollinger Band 1.0029
Percent B (%b) 1.15
BandWidth 35.509267
MACD Line 0.0377
MACD Signal Line -0.0039
MACD Histogram 0.0416
Fundamentals Value
Market Cap 23.98 Million
Num Shares 16 Million
EPS -4.08
Price-to-Earnings (P/E) Ratio -0.37
Price-to-Sales 129.29
Price-to-Book 8.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.64
Resistance 3 (R3) 1.63 1.59 1.61
Resistance 2 (R2) 1.59 1.55 1.59 1.60
Resistance 1 (R1) 1.54 1.53 1.57 1.55 1.60
Pivot Point 1.50 1.50 1.51 1.50 1.50
Support 1 (S1) 1.45 1.46 1.48 1.46 1.40
Support 2 (S2) 1.41 1.44 1.41 1.40
Support 3 (S3) 1.36 1.41 1.39
Support 4 (S4) 1.37